¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º =BsV`p7rU  
fn#8=TIDf  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ )^h6'h`  
+>w]T\[1~  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) 0ju1>.p  
uGKjZi  
1. ICAM-1 k_=SDm a  
Ae)xFnuq3  
2. interleukin 12(IL-12) #u<Qc T@  
gU9{~-9}  
3. tumor infiltrating lymphocyte UNI< r  
Er~17$b  
4. TCR/CD3 complex ,N/@=As9$  
f49kf**  
5. hematopoietin receptor family ^s,3*cAU  
LyUn!zV$(  
6. individual idiotype(IdI) ! \] ^c  
aCQtE,.  
7. integrin ^Fk;t  
tobE3Od4  
8. colony-stimulatory factor (CSF) 6|97;@94  
dzcF1 5H1  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©  CB7dr&>  
| %_C$s%  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? (1/Sf&2i  
:\](m64z;  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ *miG<  
S :HOlJze  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ/iW+<@Mas  
H7O~So*N5  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ LPs%^*8(2  
",r v%i2 f  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) t Zxx#v`  
s"L&y <?)  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ HC0juT OiO  
$C16}^  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) KbJ6U75|f  
D#jwI,n}x  
3. immunoglobulin superfamily (IgSF) ET*A0rt  
+in)(a.  
4. selectin NP>v @jO  
:@w~*eK~  
5. anti-idiotypic antibody (¦ÁId) >}k*!J|  
goM;Pf "<  
6. major histocompatibility complex(MHC) ~tUZQ5"  
ODJ"3 J  
7. immunotolerance q 4BXrEOw  
bLT3:q#s  
8. biological reponse modifier(BRM) 3}L3n*Ft#.  
zK0M WyXO  
9. immune reponse gene (Ir gene) K^{j$  
[*%lm9 x  
10. reshaped antibody (or reconstituted antibody) /N0mF< P  
#rHMf%0  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v}>g* @  
g5BL"Dn  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ Gm+D1l i  
l,n_G/\  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? p{?duq=  
b~;:[ #  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 1I;q@g0  
RqROl!6  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? % :G78.  
P IG,a~  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ ^;II@n i  
|E13W  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? cg )(L;  
HOD?i_  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ f}dlQkZ(  
( w4XqVT  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ \] Y<d  
:F d1k Jm  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? UAjN  
1uo |a  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ JKKp5~_~  
/A5=L<T6F  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: UXZ3~/L5 O  
52^3N>X4X  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: +4J'> dr  
W'Gh:73'}  
ÃâÒßѧ /XG7M=A$o  
T7YJC,^m  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 5hqXMs  
]Vf p,"op  
1. CD8 [YQtX_;w  
+VIEDV+   
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Jv(E '"H  
uUl ;}W  
3. immunoglobulin fold(Ig fold) HJr*\%D}1  
d*!H&1L  
4. cadherin (Ca-dependent cell adhesion moleculers) qPN  
;8F6a:\v  
5. idiotype-anti-idiotypic antibody immune network theory KW0KXO06a  
v&sp;%I6=  
6. HLA class II antigen YC{7;=P f  
uPFbKSJj  
7. complementarity-determining region (CDR) 84(jg P  
HDo=WqG  
8. perforin(or pore-forming protein ,PFP) b9f5  
RplcM%YJn  
9. high affinity IL-2 receptor L8;`*H  
ieyqp~+|4$  
10. artificial active immunization a(U/70j  
ZDr TPnA[  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© or ` "{wop  
BD ,3JDqT  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ@XF/hhGE_y  
)o_$AbPt  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Zfr?(y+3  
4p&SlJ  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ 3TD!3p8  
$r)nvf`\  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ XG6UV('  
h 9{'w  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 20uR?/|@  
j@s,5:;[  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Xp3cYS*u  
`!T6#6h  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ q} R"  
;,&1  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ? Kn~fs8  
whg?X&j\V  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ I-q@@! =  
WS0RvBvb  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 'W j Q  
5G=CvGu  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© J`3 p Xc$.  
4d3PF`,H`  
1. immunoglobulin gene rearrangement ,G,T&W  
yHoj:f$$x  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Z)(C7,Xu  
2S8/ lsB  
3. flow cytometry(FCM) %P9Zx!i>  
S?=2GY  
4. carrier effect ^f1}:g  
?z60b=f8  
5. positive selection of T lymphocytes in thymus Fk 1M5Dm  
F:M3^I  
6. mouse TH1(Th1) and TH2(Th2) subsets ]0dp^%  
{{=7mbc  
7. perforin (pore-forming protein ,PFP) n|L.d BAs]  
")(1z@  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) } `  
ScfW;  
9. SH-2(src-homology region 2) ^ tm,gh  
-acW[$t  
10. Ab2¦Â (internal image) Cl>'K*$F  
sbNCviKP  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 1p9f& w  
.f&,~$e4  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? C `knFGb  
fX} dh 9  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? [>?B`1;@  
^X0<ZI  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ0VsrAV0  
+69sG9BA  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ |$9k z31  
]rHdG^0uss  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠpU`Q[HOs  
UTm X"Li  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) <t gJ-rnL  
b^5rV5d  
ÃâÒßѧרҵ£º 7PP76$  
kV6T#RVob  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ aeE9dV~  
i>q]U:U  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? +lU:I  
],&WA?>G  
´«È¾²¡Ñ§×¨Òµ£º HRje4=:  
SS@# $t:  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 4 K{4=uU  
&FIPEe#n  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ -&D~TL#  
&D>e>]E|P  
Ïû»¯×¨Òµ£º &T}~h^/t  
W<u63P  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ KE&Y~y8O\  
C B =H1+  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? AAxY{Z-4  
*pyi;  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ }*hY#jo1  
Y)g7 E"  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© j#9p 0[  
;Q:^|Fw!F  
1. Fas(CD95)/FasL Txj%o5G  
U\&kT/6vh  
2. common chain of cytokine receptor :@I?JSi  
|Vs| &0  
3 . TCR/CD3 complex  L,!Z  
|{k;p fPV  
4. negaive selection of thymocytes LDN'o1$qo  
h6}oRz9=g  
5. artificial active immune I1=YSi;A  
s03 DL  
6. anti-idiotypic J vw~b\  
W@GcE;#-  
7. IgSF aSi:(w  
^QTl (L  
8. Integrin 0I* ^VGZ  
O?L _9L*  
9. chemokine M6vW}APH[n  
<~!7?ak  
10. B7/CD28 ;XSRG*3j~4  
"tBdz V  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© 3M 8P%  
}P#%aE&-  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ VG*BAFs  
d*khda;Vj  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ N*$<Kjw  
Bs =V-0  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 73P=<3  
"zc@(OA[z  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 6_ =qpP-?  
,*Y*ov23aQ  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ @/l{  
MB" uJUk  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ y GT"k,a  
C6,GgDH`  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #HWz .Wb  
d#Sc4xuf  
1. B7/CD28 [6K2V:6:  
h?j;*|o-  
2. Th1 subset Vo+d3  
o+;=C@,'  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© [q cT?h  
z@>z.d4  
4. antibody affinity maturation gGw6c" FRQ  
KSIH1E  
5. AP-1 |xZDc6HDW  
~'dnrhdme  
6. single chain variable fragment£¨ScFv£© Ky|Hi3?  
\hdR&f5q  
7. NK cell receptor 0t}=F 4@&a  
5 usfyY]z  
8. Zinkernagel-Doherty phenomenon }U7>_b2  
583ej2HPg  
9. Ig fold [?RLvhU|  
jPP aL]  
10. CD40/CD40L Vm'ReH  
}1TfKS]m>  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© nf,>l0,,'  
Il2DZ5- )  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Id]WKL:  
fdho`juFa  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 5U|f"3&8  
[aO"9  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ?8-e@/E#x  
1(w0* `  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ x?:WR*5w  
EM vV  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ k :7UU4M 5  
\VHi   
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ;Zj Qy,H%  
g.DgJX&i  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ GPP~*+n  
~lCG37  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©  =!U{vT  
t@}<&{zk  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© \5s!lv*&  
>P\T nb"Q\  
1.Co-stimulators (or co-stimulating molecules) VxjH B?)  
{nryAXK  
2.NK-kB Mk@_uPm  
'G-VhvM v  
3.Immunoglobulin superfamily <+_OgF1G  
w$Dp m.0(  
4.antigen-presenting cell (APC) nn#A-x}~;b  
_<t3~{qUT  
5.death domain %3xH<$Gq5  
yaR|d3ef?4  
6.CCR and CXCR aEZl ICpU7  
7t@j j%F  
7.Lectin (or mitogen) t$\]6RU  
?)]sfJG  
8.Clusters of differentiation, CD) vf5[x!4  
!o*oT}6n  
9.B7 family diTzolY7  
K<s\:$VVh  
10.Cytotoxic T lymphocyte, CTL) _BR>- :Jr  
{_k 6t  
11.IL-15 and IL-15 receptor (IL-15R) w' L;`k;Q  
dZnq 96<:|  
12.MHC restriction nH[@ EL  
\9ap$  
13.Affinity-chromatography [f O]oTh  
Lo;T\C N  
14.Cyctosprin A, CsA P6IhpB59  
f3yZx!K_Br  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) zEks4yd  
*Ru Uf  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© N k^#Sa?  
Dm4\Rld{  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 \J1Jn~  
u9VJ{F  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ %PkJ7-/b|^  
6J&L5E  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 0eUsvzz 15  
IClnh1=  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© \&W~nYXq"  
F;MFw2G  
ÃâÒßѧרҵ£º u1>|2D  
a2p<HW;)m  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ BQw#PXp3  
501|Y6ptl  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ j_ :4_zdBy  
b`%/ *  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ G]5'U"cj3  
PW.W.<CL  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) <\yM{ V\  
oYqlN6n,=6  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) c: #1Aym  
`Jz"rh-M  
1. ADCC(antibody dependent cell-mediated cytotoxicity) 4$vya+mAk5  
.eJ4F -V  
2. »·æß¾úËØ(cyclosporin) L6U[H#3(  
#msk'MVt  
3. KIR(killer cell inhibitory receptor) G?8,&jP~T  
J}<k`af  
4. HLDA(human leucocyte differentiation antigen) ]36R_Dp  
O2A Z|[*I  
5. Interleukin 18(IL-18) ggX'`bK  
Q{mls  
6. ÕûºÏËØ(integrin) m"@M~~bh  
`EV[uj&1S  
7. Fas/FasL l=bB,7gL  
k,b(MAiQ0  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Gl}=Q7  
'{U56^b]  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) E%jOJA  
USe"1(|E  
10. Th1/Th2 F]SexP4:A  
<@5#  
11. »ùÒòÒßÃç(DNAÒßÃç) l0[jepmpiT  
c?b?x 6 2  
12. chemokines and chemokine receptor N$?mula  
w doA>a?q  
13. ÃâÒßÄÍÊÜ nN/v7^^  
6$ @Pk<w  
14. ¹²´Ì¼¤·Ö×Ó GEIMCg(TRj  
E{ Y0TZ+  
15. ËÀÍö½á¹¹Óò(death domain) )v8;\1`s:  
K'N\"Y?>  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) BeaX 0#\  
[ ,|KVc=&H  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? aztP`S$h  
Joq9.%7Q  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠZ(*n ZT,  
@MAk/mb &  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î M+)%gnq`u  
RAXqRP,iw  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ \9@*Jgpd6*  
i LK8Wnrq  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå D\N-ye1LE  
PFUb\AY  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ L'"20=sf  
7b:oz3?PI  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) yTkYPx  
a%*W^R9Ls  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£  @*%Q,$  
roj/GZAy"  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ ;=*b:y Y  
#}:VZ2Z  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»